Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 5:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 1,712 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Dried Clear all
Completed Not applicable Interventional

A Study to Evaluate the Safety and Effectiveness of Restylane-Defyne for Punctual Occlusion

NCT03709641
View directory record Official record
Conditions
Mild to Moderate Dry Eye Disease
Interventions
Restylane Defyne
Device
Lead sponsor
John C Meyer, MD
Other
Eligibility
21 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 10, 2018 · Synced Oct 21, 2026, 5:25 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca

NCT02688556
View directory record Official record
Conditions
Keratoconjunctivitis Sicca
Interventions
cyclosporine, vehicle of OTX-101
Drug
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
18 Years and older
Enrollment
745 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
3
States / cities
Rancho Cordova, California • Edgewood, Kentucky • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 29, 2022 · Synced Oct 21, 2026, 5:25 PM EDT
Recruiting Not applicable Interventional

Silicone Gel vs. Estrogen Vaginal Cream for the Management of Genitourinary Syndrome of Menopause

NCT05672901
View directory record Official record
Conditions
Genitourinary Syndrome of Menopause
Interventions
StrataMGT, Estrace 0.01% Vaginal Cream
Device · Drug
Lead sponsor
Stratpharma AG
Industry
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Laguna Hills, California • Miami, Florida • Johns Creek, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Oct 21, 2026, 5:25 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

T30 for Astigmatism in Digital Device Users

NCT06266728
View directory record Official record
Conditions
Contact Lens Complication, Astigmatism, Refractive Errors
Interventions
Total30 for Astigmatism Contact Lenses
Device
Lead sponsor
Southern College of Optometry
Other
Eligibility
18 Years to 40 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
2
States / cities
Pittsburg, Kansas • Coldwater, Mississippi
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Oct 21, 2026, 5:25 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

ABSORB (Amount of Blueberries So Older Adults Reap Benefits)

NCT05937165
View directory record Official record
Conditions
Depressive Symptoms, Aging
Interventions
Freeze-dried Blueberry Powder
Other
Lead sponsor
Hebrew SeniorLife
Other
Eligibility
65 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Roslindale, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 21, 2026, 5:25 PM EDT
Completed Not applicable Interventional Results available

Ridge Preservation After Tooth Extraction Using Cortical Versus Cancellous Freeze Dried Bone Allograft

NCT01588444
View directory record Official record
Conditions
Tooth Extraction
Interventions
cortical FDBA, Cancellous FDBA
Device
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
19 Years to 99 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 22, 2015 · Synced Oct 21, 2026, 5:25 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Evaluating a Potential Pharmacokinetic Kratom-oxycodone Interaction Concurrent With Clinical Endpoints

NCT05846451
View directory record Official record
Conditions
Herbal Interaction
Interventions
Kratom, Oxycodone
Dietary Supplement · Drug
Lead sponsor
Washington State University
Other
Eligibility
21 Years to 45 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 21, 2026, 5:25 PM EDT
Completed Not applicable Interventional Results available

Acute Comfort and Blur of Systane Ultra and Systane

NCT00748865
View directory record Official record
Conditions
Dry Eye
Interventions
Systane Ultra Lubricant Eye Drops, Systane Lubricant Eye Drops
Other
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Feb 2, 2012 · Synced Oct 21, 2026, 5:25 PM EDT
Completed Phase 1 Interventional Results available

Safety and Efficacy of Topical Tacrolimus 0.05% in the Treatment of Ocular Graft-Versus-Host Disease

NCT01977781
View directory record Official record
Conditions
Ocular GVHD
Interventions
Tacrolimus, Methylprednisolone Sodium Succinate
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Oct 21, 2026, 5:25 PM EDT
Completed Not applicable Interventional Results available

Evaluation of the Safety and Effectiveness of the Oculeve Intranasal Lacrimal Neurostimulator in Patients With Dry Eye

NCT02313454
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Intranasal Tear Neurostimulator
Device
Lead sponsor
Allergan
Industry
Eligibility
22 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 31, 2020 · Synced Oct 21, 2026, 5:25 PM EDT
Completed Phase 2 Interventional Results available

Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of SAR440340 (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)

NCT03546907
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
SAR440340, Placebo, Any Inhaled Corticosteroids as prescribed by treating physician as standard of care, Any Long Acting Beta Agonist as prescribed by treating physician as standard of care, Any Long Acting Muscarinic Agonist as prescribed by treating physician as standard of care, Any short-acting β agonist as prescribed by treating physician as standard of care
Drug
Lead sponsor
Sanofi
Industry
Eligibility
40 Years to 75 Years
Enrollment
343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
16
States / cities
Los Angeles, California • Riverside, California • Rolling Hills Estates, California + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2022 · Synced Oct 21, 2026, 5:25 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

HIV/STD Risk and PrEP Implementation Messaging Among Gay, Bisexual, and Other Men Who Have Sex With Men

NCT06183502
View directory record Official record
Conditions
Sexually Transmitted Infections, Gay, Pre Exposure Prophylaxis
Interventions
Quantitative survey, HIV and STI testing, Qualitative Assessment
Behavioral · Procedure
Lead sponsor
Emory University
Other
Eligibility
18 Years and older · Male only
Enrollment
675 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
3
States / cities
San Diego, California • Atlanta, Georgia • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 21, 2026, 5:25 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Cardioprotective Effects of Freeze Dried Grape Powder on Blood Pressure and Plasma Lipids/Lipoproteins

NCT03659695
View directory record Official record
Conditions
Cardiovascular Risk Factor
Interventions
Grape Powder, Placebo Powder
Dietary Supplement
Lead sponsor
University of Arizona
Other
Eligibility
30 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 15, 2024 · Synced Oct 21, 2026, 5:25 PM EDT
Completed Not applicable Interventional

Microcurrent Stimulation Therapy for Nonexudative Age-related Macular Degeneration (i-SIGHT)

NCT05447650
View directory record Official record
Conditions
Age-Related Macular Degeneration, Dry Age-related Macular Degeneration, Nonexudative Age-related Macular Degeneration
Interventions
i-Lumen(TM) AMD, i-Lumen(TM) AMD Sham
Device
Lead sponsor
i-Lumen Scientific, Inc.
Industry
Eligibility
50 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
10
States / cities
Phoenix, Arizona • Walnut Creek, California • Lemont, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2025 · Synced Oct 21, 2026, 5:25 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Functionally-tailored Oral Care Intervention for Community-dwelling Older Adults With Dementia and Their Caregivers

NCT04238520
View directory record Official record
Conditions
Dementia, Cognitive Impairment
Interventions
Functionally Tailored Oral Care Intervention, Control Intervention
Behavioral
Lead sponsor
Xi Chen
Other
Eligibility
18 Years to 100 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Apr 25, 2025 · Synced Oct 21, 2026, 5:25 PM EDT
Active, not recruiting Not applicable Interventional

Matrion Decellularized Placental Membrane Versus Conventional Wound Management in Subjects With Diabetic Foot Ulcers

NCT07116876
View directory record Official record
Conditions
Diabetic Foot Ulcer (DFU), Lower Extremity
Interventions
Graft Application, Wound Dressing Material
Other
Lead sponsor
LifeNet Health
Industry
Eligibility
21 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
17
States / cities
Tucson, Arizona • Castro Valley, California • Fresno, California + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 21, 2026, 5:25 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of Mosliciguat in PH-ILD

NCT06635850
View directory record Official record
Conditions
Pulmonary Hypertension, Interstitial Lung Disease, Lung Diseases, Vascular Diseases, Cardiovascular Diseases, Fibrosis
Interventions
Mosliciguat, Dry Powder Inhaler, Placebo
Drug · Device
Lead sponsor
Pulmovant, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
25
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 21, 2026, 5:25 PM EDT
Completed Not applicable Interventional

Effects of a Standardized Freeze-dried Grape Powder on High Density Lipoprotein (HDL) Function in Metabolic Syndrome

NCT02542176
View directory record Official record
Conditions
Metabolic Syndrome X
Interventions
Freeze-dried Whole Grape Powder, Grape Powder Placebo
Other
Lead sponsor
University of Connecticut
Other
Eligibility
30 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Storrs, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 23, 2018 · Synced Oct 21, 2026, 5:25 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of Grape Consumption on Increasing the Good Bacteria in the Human Intestine

NCT05025189
View directory record Official record
Conditions
Healthy
Interventions
Table Grape Powder, Beige Diet
Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 6, 2023 · Synced Oct 21, 2026, 5:25 PM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

DOMPE -MT Neurotrophic Keratitis

NCT06947850
View directory record Official record
Conditions
Dry Eye, Neurotrophic Keratitis
Interventions
Cenegermin Ophthalmic Solution [Oxervate]
Drug
Lead sponsor
Toyos Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Oct 21, 2026, 5:25 PM EDT
Recruiting Phase 2 Interventional

Proof of Concept Study of Vaginal AZU-101 in Vulvovaginal Atrophy in Postmenopausal Women

NCT06197568
View directory record Official record
Conditions
Vulvo Vaginal Atrophy (VVA)
Interventions
Lasofoxifene Tartrate
Drug
Lead sponsor
Azure Biotech Inc.
Industry
Eligibility
45 Years to 60 Years · Female only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 21, 2026, 5:25 PM EDT
Completed Phase 1 Interventional Results available

Thrombosomes® in Bleeding Thrombocytopenic Patients

NCT03394755
View directory record Official record
Conditions
Thrombocytopenia, Hematologic Diseases, Bone Marrow Aplasia
Interventions
Thrombosomes
Biological
Lead sponsor
Cellphire Therapeutics, Inc.
Industry
Eligibility
18 Years to 74 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
6
States / cities
Duarte, California • Washington D.C., District of Columbia • Ann Arbor, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2023 · Synced Oct 21, 2026, 5:25 PM EDT
Completed Phase 4 Interventional

ASSIST-VLA: Assessment of Symptom-Specific Improvement in Diagnosed Vaginal Atrophy Following Laser Therapy

NCT07346287
View directory record Official record
Conditions
Vaginal Atrophy, Atrophic Vaginitis, Genitourinary Syndrome of Menopause (GSM)
Interventions
7-940
Device
Lead sponsor
Stratpharma AG
Industry
Eligibility
18 Years and older · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Laguna Hills, California
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 21, 2026, 5:25 PM EDT
Recruiting Phase 4 Interventional

A Study of Inhaled Treprostinil (LIQ861) in Adults With Pulmonary Arterial Hypertension Transitioning From Oral Selexipag

NCT07759804
View directory record Official record
Conditions
Pulmonary Arterial Hypertension (PAH)
Interventions
LIQ861 (treprostinil) inhalation powder
Combination Product
Lead sponsor
Liquidia Technologies, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Columbus, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 21, 2026, 5:25 PM EDT